Li Jing, Wang Yu, Tao Jun, Su Xiaodan, Zhu Feipeng, Lu Wei, Han Xiaolin, Dang Meng, Weng Lixing
Key Laboratory for Organic Electronics & Information Displays and Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials, Jiangsu National Synergetic Innovation Centre for Advanced Materials, Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Bioinorg Chem Appl. 2024 Feb 1;2024:6618388. doi: 10.1155/2024/6618388. eCollection 2024.
Photodynamic therapy (PDT) has received increasing attention for tumor therapy due to its minimal invasiveness and spatiotemporal selectivity. However, the poor targeting of photosensitizer and hypoxia of the tumor microenvironment limit the PDT efficacy. Herein, eccentric hollow mesoporous organic silica nanoparticles (EHMONs) are prepared by anisotropic encapsulation and hydrothermal etching for constructing PDT nanoplatforms with targeting and hypoxia-alleviating properties. The prepared EHMONs possess a unique eccentric hollow structure, a uniform size (300 nm), a large cavity, and ordered mesoporous channels (2.3 nm). The EHMONs are modified with the mitochondria-targeting molecule triphenylphosphine (CTPP) and photosensitizers chlorin e6 (Ce6). Oxygen-carrying compound perfluorocarbons (PFCs) are further loaded in the internal cavity of EHMONs. Hemolytic assays and toxicity experiments show that the EHMONs-Ce6-CTPP possesses very good biocompatibility and can target mitochondria of triple-negative breast cancer, thus increasing the accumulation of photosensitizers Ce6 at mitochondria after entering cancer cells. The EHMONs-Ce6-CTPP@PFCs with oxygen-carrying ability can alleviate hypoxia after entering in the cancer cell. Phantom and cellular experiments show that the EHMONs-Ce6-CTPP@PFCs produce more singlet oxygen reactive oxygen species (ROSs). Thus, in vitro and in vivo experiments demonstrated that the EHMONs-Ce6-CTPP@PFCs showed excellent treatment effects for triple-negative breast cancer. This research provides a new method for a targeting and oxygen-carrying nanoplatform for enhancing PDF effectiveness.
光动力疗法(PDT)因其微创性和时空选择性,在肿瘤治疗中受到越来越多的关注。然而,光敏剂靶向性差以及肿瘤微环境缺氧限制了PDT的疗效。在此,通过各向异性封装和水热蚀刻制备了偏心中空介孔有机硅纳米颗粒(EHMONs),以构建具有靶向和缓解缺氧特性的PDT纳米平台。所制备的EHMONs具有独特的偏心中空结构、均匀的尺寸(300nm)、大的空腔和有序的介孔通道(2.3nm)。EHMONs用靶向线粒体的分子三苯基膦(CTPP)和光敏剂二氢卟吩e6(Ce6)进行修饰。载氧化合物全氟碳(PFCs)进一步负载在EHMONs的内腔中。溶血试验和毒性实验表明,EHMONs-Ce6-CTPP具有非常好的生物相容性,并且可以靶向三阴性乳腺癌的线粒体,从而在进入癌细胞后增加光敏剂Ce6在线粒体中的积累。具有载氧能力的EHMONs-Ce6-CTPP@PFCs在进入癌细胞后可以缓解缺氧。模型和细胞实验表明,EHMONs-Ce6-CTPP@PFCs产生更多的单线态氧活性氧(ROSs)。因此,体外和体内实验表明,EHMONs-Ce6-CTPP@PFCs对三阴性乳腺癌显示出优异的治疗效果。本研究为增强光动力疗法效果的靶向和载氧纳米平台提供了一种新方法。